Risk factor
Resilient to price shocks
Profitability factor
Very low or no dividends
About
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used...
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, r
Target Price
The average target price of VIMIAN.ST is 31 and suggests 24% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell